COVID-19 Impact on Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Status and Forecast 2020-2026

September 2020 | 95 pages | ID: C1E594F2FCBAEN
QYResearch

Abstracts

This report focuses on the global Paroxysmal Nocturnal Hemoglobinuria Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Paroxysmal Nocturnal Hemoglobinuria Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Achillion Pharmaceuticals Inc
• Akari Therapeutics Plc
• Alexion Pharmaceuticals Inc
• Alnylam Pharmaceuticals Inc
• Amgen Inc
• Apellis Pharmaceuticals Inc
• F. Hoffmann-La Roche Ltd
• ISU ABXIS Co Ltd
• Novartis AG
• NovelMed Therapeutics Inc
• Omeros Corp
• Ra Pharmaceuticals Inc
• Regeneron Pharmaceuticals Inc
• Regenesance BV

Market segment by Type, the product can be split into

• ACH-4471
• ALN-CC5
• ALXN-1210
• AMY-101
• APL-2
• Others

Market segment by Application, split into

• Hospital
• Clinic
• Others

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Paroxysmal Nocturnal Hemoglobinuria Treatment status, future forecast, growth opportunity, key market and key players.
• To present the Paroxysmal Nocturnal Hemoglobinuria Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Paroxysmal Nocturnal Hemoglobinuria Treatment are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue
1.4 Market Analysis by Type
  1.4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 ACH-4471
  1.4.3 ALN-CC5
  1.4.4 ALXN-1210
  1.4.5 AMY-101
  1.4.6 APL-2
  1.4.7 Others
1.5 Market by Application
  1.5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application: 2020 VS 2026
  1.5.2 Hospital
  1.5.3 Clinic
  1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Paroxysmal Nocturnal Hemoglobinuria Treatment Industry Impact
  1.6.1 How the Covid-19 is Affecting the Paroxysmal Nocturnal Hemoglobinuria Treatment Industry
    1.6.1.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Paroxysmal Nocturnal Hemoglobinuria Treatment Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Paroxysmal Nocturnal Hemoglobinuria Treatment Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Perspective (2015-2026)
2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Growth Trends by Regions
  2.2.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Share by Regions (2015-2020)
  2.2.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Strategy
  2.3.6 Primary Interviews with Key Paroxysmal Nocturnal Hemoglobinuria Treatment Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Market Size
  3.1.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Revenue (2015-2020)
  3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Players (2015-2020)
  3.1.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio
  3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2019
3.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Key Players Head office and Area Served
3.4 Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Product Solution and Service
3.5 Date of Enter into Paroxysmal Nocturnal Hemoglobinuria Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Type (2015-2020)
4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Type (2021-2026)

5 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)
5.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2020)
6.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Key Players in North America (2019-2020)
6.3 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
6.4 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2020)
7.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Key Players in Europe (2019-2020)
7.3 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
7.4 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)

8 CHINA

8.1 China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2020)
8.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Key Players in China (2019-2020)
8.3 China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
8.4 China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2020)
9.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Key Players in Japan (2019-2020)
9.3 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
9.4 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2020)
10.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)

11 INDIA

11.1 India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2020)
11.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Key Players in India (2019-2020)
11.3 India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
11.4 India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2020)
12.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
12.4 Central & South America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Achillion Pharmaceuticals Inc
  13.1.1 Achillion Pharmaceuticals Inc Company Details
  13.1.2 Achillion Pharmaceuticals Inc Business Overview and Its Total Revenue
  13.1.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
  13.1.4 Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020))
  13.1.5 Achillion Pharmaceuticals Inc Recent Development
13.2 Akari Therapeutics Plc
  13.2.1 Akari Therapeutics Plc Company Details
  13.2.2 Akari Therapeutics Plc Business Overview and Its Total Revenue
  13.2.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
  13.2.4 Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
  13.2.5 Akari Therapeutics Plc Recent Development
13.3 Alexion Pharmaceuticals Inc
  13.3.1 Alexion Pharmaceuticals Inc Company Details
  13.3.2 Alexion Pharmaceuticals Inc Business Overview and Its Total Revenue
  13.3.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
  13.3.4 Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
  13.3.5 Alexion Pharmaceuticals Inc Recent Development
13.4 Alnylam Pharmaceuticals Inc
  13.4.1 Alnylam Pharmaceuticals Inc Company Details
  13.4.2 Alnylam Pharmaceuticals Inc Business Overview and Its Total Revenue
  13.4.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
  13.4.4 Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
  13.4.5 Alnylam Pharmaceuticals Inc Recent Development
13.5 Amgen Inc
  13.5.1 Amgen Inc Company Details
  13.5.2 Amgen Inc Business Overview and Its Total Revenue
  13.5.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
  13.5.4 Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
  13.5.5 Amgen Inc Recent Development
13.6 Apellis Pharmaceuticals Inc
  13.6.1 Apellis Pharmaceuticals Inc Company Details
  13.6.2 Apellis Pharmaceuticals Inc Business Overview and Its Total Revenue
  13.6.3 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
  13.6.4 Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
  13.6.5 Apellis Pharmaceuticals Inc Recent Development
13.7 F. Hoffmann-La Roche Ltd
  13.7.1 F. Hoffmann-La Roche Ltd Company Details
  13.7.2 F. Hoffmann-La Roche Ltd Business Overview and Its Total Revenue
  13.7.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
  13.7.4 F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
  13.7.5 F. Hoffmann-La Roche Ltd Recent Development
13.8 ISU ABXIS Co Ltd
  13.8.1 ISU ABXIS Co Ltd Company Details
  13.8.2 ISU ABXIS Co Ltd Business Overview and Its Total Revenue
  13.8.3 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
  13.8.4 ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
  13.8.5 ISU ABXIS Co Ltd Recent Development
13.9 Novartis AG
  13.9.1 Novartis AG Company Details
  13.9.2 Novartis AG Business Overview and Its Total Revenue
  13.9.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
  13.9.4 Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
  13.9.5 Novartis AG Recent Development
13.10 NovelMed Therapeutics Inc
  13.10.1 NovelMed Therapeutics Inc Company Details
  13.10.2 NovelMed Therapeutics Inc Business Overview and Its Total Revenue
  13.10.3 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
  13.10.4 NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
  13.10.5 NovelMed Therapeutics Inc Recent Development
13.11 Omeros Corp
  10.11.1 Omeros Corp Company Details
  10.11.2 Omeros Corp Business Overview and Its Total Revenue
  10.11.3 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
  10.11.4 Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
  10.11.5 Omeros Corp Recent Development
13.12 Ra Pharmaceuticals Inc
  10.12.1 Ra Pharmaceuticals Inc Company Details
  10.12.2 Ra Pharmaceuticals Inc Business Overview and Its Total Revenue
  10.12.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
  10.12.4 Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
  10.12.5 Ra Pharmaceuticals Inc Recent Development
13.13 Regeneron Pharmaceuticals Inc
  10.13.1 Regeneron Pharmaceuticals Inc Company Details
  10.13.2 Regeneron Pharmaceuticals Inc Business Overview and Its Total Revenue
  10.13.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
  10.13.4 Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
  10.13.5 Regeneron Pharmaceuticals Inc Recent Development
13.14 Regenesance BV
  10.14.1 Regenesance BV Company Details
  10.14.2 Regenesance BV Business Overview and Its Total Revenue
  10.14.3 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
  10.14.4 Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
  10.14.5 Regenesance BV Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Paroxysmal Nocturnal Hemoglobinuria Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue
Table 3. Ranking of Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of ACH-4471
Table 6. Key Players of ALN-CC5
Table 7. Key Players of ALXN-1210
Table 8. Key Players of AMY-101
Table 9. Key Players of APL-2
Table 10. Key Players of Others
Table 11. COVID-19 Impact Global Market: (Four Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Forecast Scenarios)
Table 12. Opportunities and Trends for Paroxysmal Nocturnal Hemoglobinuria Treatment Players in the COVID-19 Landscape
Table 13. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 14. Key Regions/Countries Measures against Covid-19 Impact
Table 15. Proposal for Paroxysmal Nocturnal Hemoglobinuria Treatment Players to Combat Covid-19 Impact
Table 16. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 17. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 18. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 19. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Regions (2015-2020)
Table 20. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 21. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Regions (2021-2026)
Table 22. Market Top Trends
Table 23. Key Drivers: Impact Analysis
Table 24. Key Challenges
Table 25. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth Strategy
Table 26. Main Points Interviewed from Key Paroxysmal Nocturnal Hemoglobinuria Treatment Players
Table 27. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Players (2015-2020) (Million US$)
Table 28. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Players (2015-2020)
Table 29. Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2019)
Table 30. Global Paroxysmal Nocturnal Hemoglobinuria Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 31. Key Players Headquarters and Area Served
Table 32. Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Product Solution and Service
Table 33. Date of Enter into Paroxysmal Nocturnal Hemoglobinuria Treatment Market
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020) (Million US$)
Table 36. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Share by Type (2015-2020)
Table 37. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type (2021-2026)
Table 38. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Share by Application (2015-2020)
Table 39. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020) (Million US$)
Table 40. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Share by Application (2021-2026)
Table 41. North America Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (2019-2020) (Million US$)
Table 42. North America Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share (2019-2020)
Table 43. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020) (Million US$)
Table 44. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2015-2020)
Table 45. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020) (Million US$)
Table 46. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2015-2020)
Table 47. Europe Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (2019-2020) (Million US$)
Table 48. Europe Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share (2019-2020)
Table 49. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020) (Million US$)
Table 50. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2015-2020)
Table 51. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020) (Million US$)
Table 52. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2015-2020)
Table 53. China Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (2019-2020) (Million US$)
Table 54. China Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share (2019-2020)
Table 55. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020) (Million US$)
Table 56. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2015-2020)
Table 57. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020) (Million US$)
Table 58. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2015-2020)
Table 59. Japan Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (2019-2020) (Million US$)
Table 60. Japan Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share (2019-2020)
Table 61. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020) (Million US$)
Table 62. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2015-2020)
Table 63. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020) (Million US$)
Table 64. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2015-2020)
Table 65. Southeast Asia Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (2019-2020) (Million US$)
Table 66. Southeast Asia Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share (2019-2020)
Table 67. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020) (Million US$)
Table 68. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2015-2020)
Table 69. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020) (Million US$)
Table 70. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2015-2020)
Table 71. India Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (2019-2020) (Million US$)
Table 72. India Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share (2019-2020)
Table 73. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020) (Million US$)
Table 74. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2015-2020)
Table 75. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020) (Million US$)
Table 76. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2015-2020)
Table 77. Central & South America Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (2019-2020) (Million US$)
Table 78. Central & South America Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share (2019-2020)
Table 79. Central & South America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020) (Million US$)
Table 80. Central & South America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2015-2020)
Table 81. Central & South America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020) (Million US$)
Table 82. Central & South America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2015-2020)
Table 83. Achillion Pharmaceuticals Inc Company Details
Table 84. Achillion Pharmaceuticals Inc Business Overview
Table 85. Achillion Pharmaceuticals Inc Product
Table 86. Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (Million US$)
Table 87. Achillion Pharmaceuticals Inc Recent Development
Table 88. Akari Therapeutics Plc Company Details
Table 89. Akari Therapeutics Plc Business Overview
Table 90. Akari Therapeutics Plc Product
Table 91. Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (Million US$)
Table 92. Akari Therapeutics Plc Recent Development
Table 93. Alexion Pharmaceuticals Inc Company Details
Table 94. Alexion Pharmaceuticals Inc Business Overview
Table 95. Alexion Pharmaceuticals Inc Product
Table 96. Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (Million US$)
Table 97. Alexion Pharmaceuticals Inc Recent Development
Table 98. Alnylam Pharmaceuticals Inc Company Details
Table 99. Alnylam Pharmaceuticals Inc Business Overview
Table 100. Alnylam Pharmaceuticals Inc Product
Table 101. Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (Million US$)
Table 102. Alnylam Pharmaceuticals Inc Recent Development
Table 103. Amgen Inc Company Details
Table 104. Amgen Inc Business Overview
Table 105. Amgen Inc Product
Table 106. Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (Million US$)
Table 107. Amgen Inc Recent Development
Table 108. Apellis Pharmaceuticals Inc Company Details
Table 109. Apellis Pharmaceuticals Inc Business Overview
Table 110. Apellis Pharmaceuticals Inc Product
Table 111. Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (Million US$)
Table 112. Apellis Pharmaceuticals Inc Recent Development
Table 113. F. Hoffmann-La Roche Ltd Company Details
Table 114. F. Hoffmann-La Roche Ltd Business Overview
Table 115. F. Hoffmann-La Roche Ltd Product
Table 116. F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (Million US$)
Table 117. F. Hoffmann-La Roche Ltd Recent Development
Table 118. ISU ABXIS Co Ltd Business Overview
Table 119. ISU ABXIS Co Ltd Product
Table 120. ISU ABXIS Co Ltd Company Details
Table 121. ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (Million US$)
Table 122. ISU ABXIS Co Ltd Recent Development
Table 123. Novartis AG Company Details
Table 124. Novartis AG Business Overview
Table 125. Novartis AG Product
Table 126. Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (Million US$)
Table 127. Novartis AG Recent Development
Table 128. NovelMed Therapeutics Inc Company Details
Table 129. NovelMed Therapeutics Inc Business Overview
Table 130. NovelMed Therapeutics Inc Product
Table 131. NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (Million US$)
Table 132. NovelMed Therapeutics Inc Recent Development
Table 133. Omeros Corp Company Details
Table 134. Omeros Corp Business Overview
Table 135. Omeros Corp Product
Table 136. Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (Million US$)
Table 137. Omeros Corp Recent Development
Table 138. Ra Pharmaceuticals Inc Company Details
Table 139. Ra Pharmaceuticals Inc Business Overview
Table 140. Ra Pharmaceuticals Inc Product
Table 141. Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (Million US$)
Table 142. Ra Pharmaceuticals Inc Recent Development
Table 143. Regeneron Pharmaceuticals Inc Company Details
Table 144. Regeneron Pharmaceuticals Inc Business Overview
Table 145. Regeneron Pharmaceuticals Inc Product
Table 146. Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (Million US$)
Table 147. Regeneron Pharmaceuticals Inc Recent Development
Table 148. Regenesance BV Company Details
Table 149. Regenesance BV Business Overview
Table 150. Regenesance BV Product
Table 151. Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (Million US$)
Table 152. Regenesance BV Recent Development
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type: 2020 VS 2026
Figure 2. ACH-4471 Features
Figure 3. ALN-CC5 Features
Figure 4. ALXN-1210 Features
Figure 5. AMY-101 Features
Figure 6. APL-2 Features
Figure 7. Others Features
Figure 8. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application: 2020 VS 2026
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Paroxysmal Nocturnal Hemoglobinuria Treatment Report Years Considered
Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Regions: 2020 VS 2026
Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Players in 2019
Figure 18. Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2019
Figure 20. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Achillion Pharmaceuticals Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Achillion Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 29. Akari Therapeutics Plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Akari Therapeutics Plc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 31. Alexion Pharmaceuticals Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Alexion Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 33. Alnylam Pharmaceuticals Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Alnylam Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 35. Amgen Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Amgen Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 37. Apellis Pharmaceuticals Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Apellis Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 39. F. Hoffmann-La Roche Ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 41. ISU ABXIS Co Ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. ISU ABXIS Co Ltd Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 43. Novartis AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Novartis AG Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 45. NovelMed Therapeutics Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. NovelMed Therapeutics Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 47. Omeros Corp Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Omeros Corp Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 49. Ra Pharmaceuticals Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Ra Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 51. Regeneron Pharmaceuticals Inc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Regeneron Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 53. Regenesance BV Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Regenesance BV Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed